Real Chemistry’s CEO on biopharma’s outlook in 2024

Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

By Michael Gibney • Dec. 7, 2023

4 historic FDA approvals from 2023

This year’s many firsts included a vaccine for RSV and a drug that slows Alzheimer’s disease.

By Alexandra Pecci • Dec. 6, 2023

Explore the Trendline➔

Emerging biotech

After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.  

By PharmaVoice staff

The digital therapeutics revolution is here. Will payers play ball?

Apps, VR and more could play an increasingly vital role in the wider goals of creating value-based treatments — if the industry can get payers to sign on.

By Kelly Bilodeau • Dec. 5, 2023

The weight loss market looks unstoppable. How high could it go?

Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

By Kelly Bilodeau • Dec. 4, 2023

The fortunes and flops of pharma M&A

Hindsight offers a better perspective on why some deals are fruitful and others fail.

By Alexandra Pecci • Dec. 4, 2023

3 standout digital innovations in pharma this year

IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.

By Meagan Parrish • Dec. 1, 2023

Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help

A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.

By Kelly Bilodeau • Nov. 29, 2023

Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

By Jonathan Gardner • Nov. 29, 2023

Biopharma’s top 5 IPOs of 2023 (so far)

Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

By Alexandra Pecci • Nov. 28, 2023

The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.

By Michael Gibney • Nov. 28, 2023

As alcohol-related deaths climb, new drugs could curb the urge to drink

A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

By Kelly Bilodeau • Nov. 27, 2023

How EMD Serono plans to hit its lofty goals in R&D

The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.

By Alexandra Pecci • Nov. 27, 2023

The biopharma COO’s playbook

Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

By Alexandra Pecci • Nov. 21, 2023

Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

By Kelly Bilodeau • Nov. 20, 2023

​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

By Meagan Parrish • Nov. 17, 2023

AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

By Michael Gibney • Nov. 16, 2023

The power of genomics-based healthcare remains largely untapped

23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

By Alexandra Pecci • Nov. 15, 2023

6 ways to improve clinical trial diversity — as shown by J&J

Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

By Alexandra Pecci • Nov. 14, 2023

Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

By Kelly Bilodeau • Nov. 13, 2023

Optimizing KOL engagement and technology utilization in 2024

What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?

Nov. 13, 2023

5 of the best paid biopharma CEOs

As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

By Alexandra Pecci • Nov. 10, 2023

How pharma leaders talk about ethics in a highly criticized industry

The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

By Michael Gibney • Nov. 9, 2023

An at-home flu vaccine? If approved, it could open the door to more DIY options

A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

By Kelly Bilodeau • Nov. 8, 2023

The obesity drug effect: What medical device executives are saying

Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

By Susan Kelly • Nov. 6, 2023

The thorniest questions facing pharma, according to a leading bioethicist

Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

By Michael Gibney • Nov. 6, 2023